Michael Lahn

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 4

Top Topics

Pluripotent Stem Cells

Small Cell Lung Cancer

Top Venues

Cancer research

International journal of toxicology

Cancer research communications

Drug design, development and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Silvia Pietrobono, Fabio Sabbadini, Monica Bertolini, Domenico Mangiameli, Veronica De Vita, Federica Fazzini, Giulia Lunardi, Simona Casalino, Enza Scarlato, Valeria Merz, Camilla Zecchetto, Alberto Quinzii, Giusy Di Conza, Michael Lahn, Davide Melisi
Autotaxin secretion is a stromal mechanism of adaptive resistance to TGFβ inhibition in pancreatic ductal adenocarcinoma. Cancer research (2023)
Zoe Johnson, Chiara Tarantelli, Elisa Civanelli, Luciano Cascione, Filippo Spriano, Amy Fraser, Pritom Shah, Tyzoon Nomanbhoy, Sara Napoli, Andrea Rinaldi, Karolina Niewola-Staszkowska, Michael Lahn, Dominique Perrin, Mathias Wenes, Denis Migliorini, Francesco Bertoni, Lars van der Veen, Giusy Di Conza
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications 3 (4) (2023)
Lars van der Veen, Michael Schmitt, Marcel A Deken, Michael Lahn
Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib. International journal of toxicology (2023)
Jason D Lickliter, Hui K Gan, Mark Voskoboynik, Surein Arulananda, Bo Gao, Adnan Nagrial, Peter Grimison, Michelle Harrison, Jianjun Zou, Lianshan Zhang, Stacey Luo, Michael Lahn, Howard Kallender, Andrea Mannucci, Catello Somma, Katherine Woods, Andreas Behren, Pablo Fernandez-Penas, Michael Millward, Tarek Meniawy
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug design, development and therapy 14 (2020)